<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845338</url>
  </required_header>
  <id_info>
    <org_study_id>12331</org_study_id>
    <secondary_id>2006-002361-39</secondary_id>
    <nct_id>NCT00845338</nct_id>
  </id_info>
  <brief_title>Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity</brief_title>
  <official_title>A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to explore the effects of darifenacin in patients with
      multiple sclerosis and neurogenic detrusor overactivity. The efficacy, safety and
      tolerability of darifenacin are already well established in idiopathic detrusor overactivity.
      Patients with multiple sclerosis and neurogenic detrusor overactivity without
      detrusor-sphincter-dyssynergia (DSD) will be allocated to darifenacin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The enrollment rate at most centers was unlikely to result in the recruitment of the planned
    sample size of 40 evaluable subjects.
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in volume at first detrusor contraction as determined by urodynamics</measure>
    <time_frame>At week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detrusor pressure at first contraction</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume at first detectable leakage</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume at 10/20/30/40 cm H2O</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum cystometric bladder capacity</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day micturition diary: Micturitions</measure>
    <time_frame>At days 0, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day micturition diary: Urgency episodes</measure>
    <time_frame>At days 0, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day micturition diary: Urge urinary incontinence episodes</measure>
    <time_frame>At days 0, 14, 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Overactive Detrusor</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin (BAY79-4998)</intervention_name>
    <description>Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with multiple sclerosis for at least 6 months

          -  Neurogenic detrusor overactivity without DSD

          -  Symptoms of OAB

          -  Patients capable of completing the bladder diary

          -  Patients capable of independent toileting

          -  Patients able to swallow the study medication in accordance to the protocol

          -  Body Mass Index &gt;/= 18,8 kg/qm and &lt;/= 35,0 kg/qm

          -  documented, dated, written informed consent

        Exclusion Criteria:

          -  Treatment with drugs known to affect mainly the urinary function 14 days prior to
             starting completion of the baseline diary for Visit 2

          -  Participation in a bladder-training program

          -  Low compliance bladder (Compliance &lt;20 mL/cm H2O)

          -  DSD, Detrusor hyporeflexia / areflexia and bradykinesia / tremor of the external
             urethral sphincter

          -  Indwelling catheter or intermittent self-catheterization

          -  Patience with post-void residual (PVR) urinary volume &gt; 200 mL at baseline

          -  Urinary retention or clinically significant bladder outlet obstruction as detected by
             the investigator

          -  Clinically predominant and bothersome stress urinary incontinence

          -  Neurological diseases other than multiple sclerosis affecting urinary bladder function

          -  Any urogenital surgery within 12 month prior to Visit 1

          -  17 Additional Exclusion Criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Emmendingen</city>
        <state>Baden-Württemberg</state>
        <zip>79312</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lahr</city>
        <state>Baden-Württemberg</state>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-Württemberg</state>
        <zip>78054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Planegg</city>
        <state>Bayern</state>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oberursel</city>
        <state>Hessen</state>
        <zip>61440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mönchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mülheim</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Berka</city>
        <state>Thüringen</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2009</study_first_submitted>
  <study_first_submitted_qc>February 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>November 28, 2014</last_update_submitted>
  <last_update_submitted_qc>November 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Darifenacin</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Open Label Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

